Lung Cancer · 2012 · 25 citations · 7 references
PharmacyOncologyPharmacoeconomicsCost-effectiveness AnalysisCost-effectiveness ComparisonCost-effectiveness ModelingLung CancerLung Cancer PharmacotherapyMalignant NeoplasmsSupportive Care In CancerCancer Cost BurdenEconomic Burden Of CancerErlotinib TherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentReal-world Comparative EffectivenessReal-world Cost AssessmentThird-line Treatment
7
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.5K citations · Full text
Medicine, Oncology, Pharmacology +15
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Ming‐Sound Tsao, Akira Sakurada, Jean-Claude Cutz et al. · New England Journal of Medicine · 2005 · 1.9K citations
Medicine, Oncology, Pharmacology +14
Andrea Bezjak, Dongsheng Tu, Lesley Seymour et al. · Journal of Clinical Oncology · 2006 · 295 citations · Full text
Medicine, Oncology, Pharmacology +10
Bjørn Henning Grønberg, Roy M. Bremnes, Øystein Fløtten et al. · Journal of Clinical Oncology · 2009 · 290 citations · Full text
Medicine, Oncology, Pharmacology +16